New Orleans Magazine maps three channels feeding the peptide gray market
The explainer leans on Center for Science in the Public Interest reporting to split supply into prescription compounding, research-use-only sellers and offshore manufacturers.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 1 09:00 ETSource: New Orleans Magazine
The wire
- 01A consumer feature describes BPC-157, TB-500 and other recovery and longevity peptides moving through compounding pharmacies, research-use-only websites and international sellers with blurred boundaries between them.
- 02Clinicians and telehealth operators face patients arriving with self-sourced vials; the piece stresses compounded drugs are not FDA-evaluated for safety, effectiveness or quality before reaching patients.
- 03No new data or enforcement action here, and the article concedes access has outpaced human research for most of the peptides named.
From the source
Read at myneworleans.comUnderstanding Peptides: What are They & Do We Need to Take Them
They may be having a moment, but the science is still catching up.
